22 Recruiting Studies Using Capivasertib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Capivasertib
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
📍 Research Site — Tucson, Arizona
Hormone-Sensitive Prostate Cancer
View Study & Checklist ➔A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
📍 Research Site — Tucson, Arizona
Triple Negative Breast Neoplasms
View Study & Checklist ➔Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
📍 Research Site — Tucson, Arizona
Locally Advanced (Inoperable) or Metastatic Breast Cancer
View Study & Checklist ➔Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
📍 Research Site — Yuma, Arizona
Prostate Cancer
View Study & Checklist ➔mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
📍 M D Anderson Cancer Center — Houston, Texas
BRCA1 Mutation Carrier
View Study & Checklist ➔A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
📍 Research Site — Commack, New York
Metastatic Breast Cancer
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
📍 Dothan Hematology and Oncology — Dothan, Alabama
Breast Cancer
View Study & Checklist ➔Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
📍 Research Site — Whittier, California
Triple Negative Breast Neoplasms
View Study & Checklist ➔Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
📍 Research Site — Gilbert, Arizona
Locally Advanced (Inoperable) or Metastatic Breast Cancer
View Study & Checklist ➔Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Endometrial Adenocarcinoma
View Study & Checklist ➔Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer
📍 VA Connecticut Healthcare System West Haven Campus, West Haven, CT — West Haven, Connecticut
Advanced Urothelial Carcinoma
View Study & Checklist ➔Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
PIK3CA Mutation
View Study & Checklist ➔CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Leukemia
View Study & Checklist ➔Rash & Diarrhea Prophylaxis With Capivasertib
📍 Yale University — New Haven, Connecticut
Metastatic HR+/HER2- Breast Cancer
View Study & Checklist ➔A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
📍 Research Site — Rialto, California
Moderate Hepatic Impairment
View Study & Checklist ➔IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
📍 M D Anderson Cancer Center — Houston, Texas
Advanced Endometrial Carcinoma
View Study & Checklist ➔Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
📍 University of Arizona — Tucson, Arizona
Melanoma (Skin Cancer)
View Study & Checklist ➔Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
📍 University of California Davis — Sacramento, California
Prostate Cancer
View Study & Checklist ➔A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
📍 VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
High-Risk Prostate Cancer
View Study & Checklist ➔Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Intracranial Meningioma
View Study & Checklist ➔